|
1
|
Delivering affordable cancer care in high-income countries.
|
Lancet Oncol
|
2011
|
12.79
|
|
2
|
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
|
J Clin Oncol
|
2009
|
6.44
|
|
3
|
A clinical development paradigm for cancer vaccines and related biologics.
|
J Immunother
|
2007
|
2.97
|
|
4
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
|
J Clin Oncol
|
2009
|
2.50
|
|
5
|
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
|
Eur J Cancer
|
2009
|
2.26
|
|
6
|
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.
|
Cancer Treat Rev
|
2003
|
2.08
|
|
7
|
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.
|
Oncoimmunology
|
2012
|
1.88
|
|
8
|
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.
|
Oncoimmunology
|
2012
|
1.78
|
|
9
|
A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe.
|
Eur J Cancer
|
2005
|
1.70
|
|
10
|
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
|
Cancer Res
|
2013
|
1.58
|
|
11
|
Trial watch: Dendritic cell-based interventions for cancer therapy.
|
Oncoimmunology
|
2012
|
1.51
|
|
12
|
Trial watch: Monoclonal antibodies in cancer therapy.
|
Oncoimmunology
|
2013
|
1.41
|
|
13
|
Trial watch: Oncolytic viruses for cancer therapy.
|
Oncoimmunology
|
2013
|
1.36
|
|
14
|
Trial Watch: Toll-like receptor agonists for cancer therapy.
|
Oncoimmunology
|
2013
|
1.35
|
|
15
|
Trial watch: Chemotherapy with immunogenic cell death inducers.
|
Oncoimmunology
|
2013
|
1.31
|
|
16
|
Trial Watch: Anticancer radioimmunotherapy.
|
Oncoimmunology
|
2013
|
1.31
|
|
17
|
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
|
Oncoimmunology
|
2012
|
1.30
|
|
18
|
Trial watch: Cardiac glycosides and cancer therapy.
|
Oncoimmunology
|
2013
|
1.21
|
|
19
|
Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction.
|
Clin Cancer Res
|
2004
|
1.19
|
|
20
|
Trial Watch: Immunostimulatory cytokines.
|
Oncoimmunology
|
2012
|
1.19
|
|
21
|
Trial Watch: Adoptive cell transfer immunotherapy.
|
Oncoimmunology
|
2012
|
1.18
|
|
22
|
Trial watch: Peptide vaccines in cancer therapy.
|
Oncoimmunology
|
2012
|
1.17
|
|
23
|
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
|
Int J Cancer
|
2002
|
1.14
|
|
24
|
Trial watch: DNA vaccines for cancer therapy.
|
Oncoimmunology
|
2013
|
1.11
|
|
25
|
Trial watch: Dendritic cell-based interventions for cancer therapy.
|
Oncoimmunology
|
2013
|
1.09
|
|
26
|
Integrated molecular portrait of non-small cell lung cancers.
|
BMC Med Genomics
|
2013
|
0.99
|
|
27
|
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.
|
Clin Cancer Res
|
2007
|
0.99
|
|
28
|
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
|
J Thorac Oncol
|
2014
|
0.98
|
|
29
|
Trial Watch: Immunostimulatory cytokines.
|
Oncoimmunology
|
2013
|
0.96
|
|
30
|
Trial Watch: Adoptive cell transfer for anticancer immunotherapy.
|
Oncoimmunology
|
2013
|
0.95
|
|
31
|
Dendritic cell-derived exosomes for cancer therapy.
|
J Clin Invest
|
2016
|
0.91
|
|
32
|
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.
|
Oncoimmunology
|
2013
|
0.91
|
|
33
|
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
|
Oncoimmunology
|
2013
|
0.86
|
|
34
|
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.
|
Cancer Res
|
2013
|
0.84
|
|
35
|
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.
|
J Immunother
|
2004
|
0.82
|
|
36
|
Potent immunomodulatory effects of the trifunctional antibody catumaxomab.
|
Cancer Res
|
2013
|
0.80
|
|
37
|
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.
|
J Clin Invest
|
2016
|
0.80
|
|
38
|
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
|
Cell Res
|
2015
|
0.77
|
|
39
|
Advances in immuno-oncology. Foreword.
|
Ann Oncol
|
2012
|
0.77
|
|
40
|
Putting Europe in the driving seat.
|
Eur J Cancer
|
2006
|
0.75
|
|
41
|
Highlights from the perspectives in melanoma XII conference.
|
Pigment Cell Melanoma Res
|
2009
|
0.75
|
|
42
|
An interview with Alexander Eggermont.
|
Mol Oncol
|
2009
|
0.75
|